STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

BACKGROUND: The management of unresectable metastatic colorectal cancer (mCRC) is a comprehensive treatment strategy involving several lines of therapy, maintenance, salvage surgery, and treatment-free intervals. Besides chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan), molecular-targeted ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Chibaudel, Benoist, Bonnetain, Franck, Tournigand, Christophe, de Larauze, Marine Hug, de Gramont, Armand, Laurent-Puig, Pierre, Paget, Jérôme, Hadengue, Alexandra, Notelet, Dominique, Benetkiewicz, Magdalena, André, Thierry, de Gramont, Aimery
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490616/
https://www.ncbi.nlm.nih.gov/pubmed/26141683
http://dx.doi.org/10.1186/s12885-015-1503-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490616/
https://www.ncbi.nlm.nih.gov/pubmed/26141683
http://dx.doi.org/10.1186/s12885-015-1503-7

Ejemplares similares